This document is a publication of a patent application (US20260083699A1) filed by Transcend Therapeutics, Inc. The application pertains to psychoactive medicines such as 2C-B, methylone, MBDB, and their analogues, along with their preparation, formulations, and use in treating psychiatric and neurological conditions and disorders. The application was filed on December 4, 2025.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in the pharmaceutical landscape for psychoactive medicines, which may be of interest to drug manufacturers and researchers in the field. Compliance officers should note this as an indicator of emerging intellectual property in this therapeutic area.